SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-021974
Filing Date
2023-05-15
Accepted
2023-05-15 08:01:27
Documents
67
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ikt-20230331.htm   iXBRL 10-Q 1656439
2 EX-31.1 ikt-ex31_1.htm EX-31.1 16894
3 EX-31.2 ikt-ex31_2.htm EX-31.2 16913
4 EX-32.1 ikt-ex32_1.htm EX-32.1 14224
5 EX-32.2 ikt-ex32_2.htm EX-32.2 14224
  Complete submission text file 0000950170-23-021974.txt   6082144

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ikt-20230331_cal.xml EX-101.CAL 34930
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ikt-20230331_pre.xml EX-101.PRE 268432
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ikt-20230331_lab.xml EX-101.LAB 355994
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ikt-20230331.xsd EX-101.SCH 45527
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ikt-20230331_def.xml EX-101.DEF 145610
61 EXTRACTED XBRL INSTANCE DOCUMENT ikt-20230331_htm.xml XML 988005
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39676 | Film No.: 23918506
SIC: 2836 Biological Products, (No Diagnostic Substances)